Literature DB >> 12204955

Specificities and opsonophagocytic activities of antibodies to pneumococcal capsular polysaccharides in sera of unimmunized young children.

Anu Soininen1, Maijastiina Karpala, Sirkka-Liisa Wahlman, Hannele Lehtonen, Helena Käyhty.   

Abstract

An enzyme immunoassay (EIA) for antibodies to pneumococcal capsular polysaccharides (Pnc PSs) detects in some cases antibodies that are cross-reactive within different Pnc PSs. Recently, it has been suggested that for detection of only serotype-specific antibodies, EIA can be modified by removing cross-reactive antibodies by absorption with an irrelevant PS, e.g., the type 22F PS. The opsonophagocytosis assay measures the functional activities of antibodies in vitro, and the results of that assay correlate with in vivo protection better than measurement of the antibody concentration by EIA. We compared these different methods for measuring antibodies to type 1, 6B, 11A, 14, 19F, and 23F Pnc PSs in the sera of unimmunized young children who had been monitored for pneumococcal carriage, acute otitis media, and acquisition of antibodies to Pnc PSs from 2 to 24 months of age. Serum samples with antibody increases after contact with a pneumococcus of a homologous serotype contained specific antibodies and often had opsonophagocytic activity (OPA) (20 of 46). In samples with antibody increases from children who had not had contact with a pneumococcus of a homologous serotype, the antibodies found to be type specific by conventional EIA were usually cross-reactive and infrequently had OPA (10 of 68). When type 22F PS absorption was used in the EIA, most of the false antibody increases were eliminated, but most of the true antibody increases were still detected and the association between the antibody concentration detected by EIA and OPA was improved. However, there were serotype-dependent differences in the frequency of OPA. Use of absorption with a heterologous PS in EIA should be encouraged, and both the specificity of EIA and the sensitivity of opsonophagocytic assays should be further evaluated and improved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12204955      PMCID: PMC120050          DOI: 10.1128/cdli.9.5.1032-1038.2002

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  23 in total

1.  Contribution of serotype-specific IgG concentration, IgG subclasses and relative antibody avidity to opsonophagocytic activity against Streptococcus pneumoniae.

Authors:  M Anttila; M Voutilainen; V Jäntti; J Eskola; H Käyhty
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

2.  Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells.

Authors:  S Romero-Steiner; D Libutti; L B Pais; J Dykes; P Anderson; J C Whitin; H L Keyserling; G M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  1997-07

Review 3.  Mechanisms of host defense against infection with Streptococcus pneumoniae.

Authors:  G A Bruyn; B J Zegers; R van Furth
Journal:  Clin Infect Dis       Date:  1992-01       Impact factor: 9.079

4.  Isotypes and opsonophagocytosis of pneumococcus type 6B antibodies elicited in infants and adults by an experimental pneumococcus type 6B-tetanus toxoid vaccine.

Authors:  G Vidarsson; S T Sigurdardottir; T Gudnason; S Kjartansson; K G Kristinsson; G Ingolfsdottir; S Jonsson; H Valdimarsson; G Schiffman; R Schneerson; I Jonsdottir
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

5.  Identification of cross-reactive antibodies with low opsonophagocytic activity for Streptococcus pneumoniae.

Authors:  M H Nahm; J V Olander; M Magyarlaki
Journal:  J Infect Dis       Date:  1997-09       Impact factor: 5.226

6.  Pneumococcal capsular polysaccharide preparations may contain non-C-polysaccharide contaminants that are immunogenic.

Authors:  X Yu; Y Sun; C Frasch; N Concepcion; M H Nahm
Journal:  Clin Diagn Lab Immunol       Date:  1999-07

7.  Correlation of opsonophagocytosis and passive protection assays using human anticapsular antibodies in an infant mouse model of bacteremia for Streptococcus pneumoniae.

Authors:  S E Johnson; L Rubin; S Romero-Steiner; J K Dykes; L B Pais; A Rizvi; E Ades; G M Carlone
Journal:  J Infect Dis       Date:  1999-07       Impact factor: 5.226

8.  Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S.

Authors:  S A Quataert; C S Kirch; L J Wiedl; D C Phipps; S Strohmeyer; C O Cimino; J Skuse; D V Madore
Journal:  Clin Diagn Lab Immunol       Date:  1995-09

9.  Serum antibodies to pneumococcal C polysaccharide in children: response to acute pneumococcal otitis media or to vaccination.

Authors:  M Koskela
Journal:  Pediatr Infect Dis J       Date:  1987-06       Impact factor: 2.129

10.  Characterization of pneumococcal specific antibodies in healthy unvaccinated adults.

Authors:  R T Coughlin; A C White; C A Anderson; G M Carlone; D L Klein; J Treanor
Journal:  Vaccine       Date:  1998-11       Impact factor: 3.641

View more
  13 in total

1.  Pneumococcal capsular polysaccharide vaccine-mediated protection against serotype 3 Streptococcus pneumoniae in immunodeficient mice.

Authors:  Haijun Tian; Avi Groner; Marianne Boes; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2007-01-12       Impact factor: 3.441

2.  Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines.

Authors:  Jan T Poolman; Carl E Frasch; Helena Käyhty; Pascal Lestrate; Shabir A Madhi; Isabelle Henckaerts
Journal:  Clin Vaccine Immunol       Date:  2009-11-04

3.  Levels of antibodies specific to tetanus toxoid, Haemophilus influenzae type b, and pneumococcal capsular polysaccharide in healthy children and adults.

Authors:  Uwe Schauer; Frank Stemberg; Christian H L Rieger; Wolfgang Büttner; Michael Borte; Simone Schubert; Helga Möllers; Frank Riedel; Udo Herz; Harald Renz; Wilhelm Herzog
Journal:  Clin Diagn Lab Immunol       Date:  2003-03

4.  Serotype-specific anti-pneumococcal IgG and immune competence: critical differences in interpretation criteria when different methods are used.

Authors:  Anne Balloch; Paul V Licciardi; Mimi L K Tang
Journal:  J Clin Immunol       Date:  2012-09-30       Impact factor: 8.317

5.  Effects of absorption with pneumococcal type 22F polysaccharide on maternal, cord blood, and infant immunoglobulin G antipneumococcal polysaccharide antibodies.

Authors:  J Inostroza; S Villanueva; K Mason; L E Leiva; R U Sorensen
Journal:  Clin Diagn Lab Immunol       Date:  2005-06

6.  Type-specific antibodies to pneumococcal capsular polysaccharide acquired either naturally or after vaccination with Prevenar in children with underlying chronic or recurrent lung diseases.

Authors:  David Navarro; Amparo Escribano; Laura Cebrián; Concepción Gimeno; Leonor García-Maset; Juan García-de-Lomas
Journal:  Clin Vaccine Immunol       Date:  2006-06

7.  Streptococcus pneumoniae serotype 1 burden in the African meningitis belt: exploration of functionality in specific antibodies.

Authors:  S Blumental; J C Moïsi; L Roalfe; M Zancolli; M Johnson; P Burbidge; R Borrow; S Yaro; J E Mueller; B D Gessner; D Goldblatt
Journal:  Clin Vaccine Immunol       Date:  2015-02-04

8.  Approach to validating an opsonophagocytic assay for Streptococcus pneumoniae.

Authors:  Branda T Hu; Xinhong Yu; Thomas R Jones; Carol Kirch; Sarah Harris; Stephen W Hildreth; Dace V Madore; Sally A Quataert
Journal:  Clin Diagn Lab Immunol       Date:  2005-02

9.  Reference ranges and cutoff levels of pneumococcal antibody global serum assays (IgG and IgG2) and specific antibodies in healthy children and adults.

Authors:  M A Rose; J Buess; Y Ventur; S Zielen; E Herrmann; J Schulze; R Schubert
Journal:  Med Microbiol Immunol       Date:  2013-03-26       Impact factor: 3.402

10.  Specificity of the antibody response to the pneumococcal polysaccharide and conjugate vaccines in human immunodeficiency virus-infected adults.

Authors:  Daniel R Feikin; Cheryl M Elie; Matthew B Goetz; Jeffrey L Lennox; George M Carlone; Sandra Romero-Steiner; Patricia F Holder; William A O'Brien; Cynthia G Whitney; Jay C Butler; Robert F Breiman
Journal:  Clin Diagn Lab Immunol       Date:  2004-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.